About Academician Wang Hongyang
Academician Wang Hongyang (王红阳) is a Professor, Doctoral Supervisor, Academician of the Chinese Academy of Engineering, and one of China's most distinguished and internationally recognized cancer biologists and translational oncologists. Based at the International Cooperation Laboratory on Signal Transduction, Changhai Hospital, Naval Medical University (Second Military Medical University), Academician Wang is globally recognized as a leading authority on the molecular mechanisms of hepatocellular carcinoma (HCC) development, progression, and metastasis, and as a pioneer of translational research that bridges fundamental cancer biology with clinical oncology practice. Her decades of research on signal transduction pathways in liver cancer — including the roles of cytokines, growth factors, and oncogenic signaling networks in HCC pathogenesis — have produced foundational insights that have shaped the international understanding of liver cancer biology and contributed to the development of novel therapeutic targets and biomarkers for HCC.
Academician Wang's scientific contributions span the full arc from basic cancer biology to clinical translation. Her laboratory at Changhai Hospital has produced landmark studies on the molecular mechanisms by which inflammatory cytokines — particularly IL-6 and its downstream signaling through STAT3 — drive hepatocellular carcinogenesis in the context of chronic hepatitis B and C infection and liver cirrhosis; on the role of the tumor microenvironment in HCC progression and immune evasion; on the identification of novel oncogenes and tumor suppressor genes in HCC; and on the development of molecular biomarkers for HCC early detection, prognosis, and treatment response prediction. Her research has been published in the world's leading scientific and medical journals — including Nature Medicine, Cancer Cell, Journal of Clinical Investigation, Hepatology, Journal of Hepatology, and Gut — and has been cited thousands of times by researchers worldwide.
While Academician Wang's primary role is as a research scientist and translational oncologist rather than a clinical surgeon, her laboratory's work directly informs the clinical management of HCC patients at Changhai Hospital and beyond — through the development of molecular biomarkers that guide treatment selection, the identification of novel therapeutic targets that are being evaluated in clinical trials, and the translation of basic science insights into improved clinical protocols for HCC surveillance, diagnosis, and treatment. Consultations arranged through CMCS connect international patients with the clinical oncology expertise of Changhai Hospital's liver cancer program, informed by the translational research leadership of Academician Wang's laboratory.
Hospital Affiliation: Changhai Hospital & Naval Medical University
Changhai Hospital (长海医霂), affiliated with Naval Medical University, is one of Shanghai's largest and most prestigious academic medical centers. Its liver cancer program — informed by the translational research of Academician Wang Hongyang's laboratory — provides comprehensive multidisciplinary management of hepatocellular carcinoma integrating hepatobiliary surgery, interventional radiology (TACE, ablation), medical oncology (sorafenib, lenvatinib, atezolizumab-bevacizumab, and other systemic therapies), radiation oncology (SBRT), and gastroenterology (HBV/HCV antiviral therapy, cirrhosis management). The hospital's active clinical trials program — informed by Academician Wang's translational research — provides access to investigational systemic therapies, immunotherapy combinations, and novel targeted agents for HCC patients who have exhausted standard treatment options.
Academician Wang's International Cooperation Laboratory on Signal Transduction maintains active research collaborations with leading cancer research centers worldwide, including institutions in the United States, Europe, and Asia, and has trained generations of cancer biologists and translational oncologists who now lead research programs across China and internationally.
Research Contributions & Clinical Impact
- Molecular mechanisms of HCC pathogenesis — landmark studies on the role of IL-6/STAT3 signaling in hepatocellular carcinogenesis; identification of novel oncogenes and tumor suppressor genes in HCC; characterization of the tumor microenvironment in HCC and its role in immune evasion and treatment resistance; mechanisms of HCC metastasis and portal vein tumor thrombus formation
- HCC biomarker development — identification and validation of novel serum and tissue biomarkers for HCC early detection, prognosis, and treatment response prediction; development of molecular signatures that complement AFP for HCC surveillance in high-risk populations; biomarkers for prediction of response to sorafenib, lenvatinib, and immunotherapy in advanced HCC
- Translational oncology and clinical trial leadership — translation of basic science discoveries into clinical protocols and investigational therapies; leadership of clinical trials evaluating novel targeted therapies and immunotherapy combinations for HCC; development of precision oncology approaches to HCC treatment selection based on tumor molecular profiling
- HCC surveillance and early detection — research on optimizing HCC surveillance strategies in high-risk populations including chronic hepatitis B and C patients and cirrhotic patients; evaluation of novel surveillance biomarkers and imaging protocols for early HCC detection
- Multidisciplinary HCC management — integration of translational research insights into clinical HCC management protocols at Changhai Hospital; tumor board leadership integrating surgery, interventional radiology, medical oncology, and radiation oncology; access to investigational therapies through clinical trials for patients with advanced or refractory HCC
Academic Legacy & Global Recognition
Academician Wang Hongyang's scientific legacy is among the most celebrated in the history of Chinese cancer research. She has authored and co-authored more than 400 peer-reviewed publications in Chinese and international journals, with landmark contributions to Nature Medicine, Cancer Cell, Journal of Clinical Investigation, Hepatology, Journal of Hepatology, and Gut. Her research has been cited thousands of times and has directly shaped the international understanding of HCC biology and the development of novel therapeutic strategies for liver cancer.
Academician Wang has received virtually every major honor in Chinese and international cancer research, including the National Natural Science Award, the Ho Leung Ho Lee Foundation Prize for Scientific and Technological Progress, and fellowship in multiple international scientific societies. Her election to the Chinese Academy of Engineering reflects the transformative impact of her research on the understanding and treatment of liver cancer in China and globally. She has trained more than 100 cancer biology and translational oncology doctoral students and postdoctoral fellows who now lead research programs across China and internationally, and her intellectual legacy is embodied in the vibrant translational oncology research community at Changhai Hospital and Naval Medical University.
Why International Patients Come to Changhai Hospital's Liver Cancer Program
For international patients with hepatocellular carcinoma — whether early-stage disease amenable to curative resection or ablation, intermediate-stage disease requiring TACE or combination therapy, advanced disease with portal vein tumor thrombus, or recurrent HCC after prior treatment — Changhai Hospital's liver cancer program offers a combination of clinical expertise, multidisciplinary treatment capability, translational research integration, and access to investigational therapies that places it among the leading HCC programs in China.
The program's particular strengths — its integration of Academician Wang's translational research insights into clinical practice, its active clinical trials program evaluating novel systemic therapies and immunotherapy combinations, and its multidisciplinary tumor board integrating surgery, interventional radiology, medical oncology, and radiation oncology — make it an especially valuable resource for patients with advanced or refractory HCC who have exhausted standard treatment options and are seeking access to investigational therapies or novel combination strategies. Treatment costs at Changhai Hospital are substantially lower than equivalent care in Western healthcare systems, and access to specialist consultation and multidisciplinary tumor board review is typically achievable within days through CMCS.
What to Expect at Your Consultation
Consultations at Changhai Hospital's liver cancer program arranged through CMCS begin with a comprehensive review of all prior imaging — including multiphasic CT or MRI of the liver, chest CT, and PET-CT for staging — AFP and other tumor marker trends, liver function tests, viral hepatitis serology and viral load, prior pathology results, and prior treatment records including surgery, TACE, ablation, and systemic therapy. CMCS will arrange certified translation of all medical records and imaging reports in advance of the consultation. The consulting hepatic oncologist will assess the tumor stage and treatment options, outline the recommended strategy with detailed rationale, and coordinate multidisciplinary tumor board review. A written English-language consultation summary is provided after every appointment, and CMCS will facilitate direct communication between Changhai Hospital's liver cancer team and the patient's home oncologist for continuity of care.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking liver cancer consultation at Changhai Hospital — informed by the translational research leadership of Academician Wang Hongyang. Our services include priority consultation scheduling, certified medical record and imaging translation, pre-consultation oncological review, surgical logistics and hospital admission coordination, on-site interpretation, and written English-language reporting of all findings and recommendations.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
0 comentarios